Newsig · Investing.com
Lilly says Foundayo has captured over 30% of new US patients on oral weight-loss drugs
Market context: LLY: Lilly's own oral weight-loss drug Foundayo gaining >30% new patient share is a direct competitive and commercial data point Bullish for LLY; strong early adoption of its oral GLP-1 could pressure injectables competitors but reinforces Lilly's obesity franchise growth
Why it matters
LLY (Eli Lilly) · Why linked: Lilly's own oral weight-loss drug Foundayo gaining >30% new patient share is a direct competitive and commercial data point Market context: Bullish for LLY; strong early adoption of its oral GLP-1 could pressure injectables competitors but reinforces Lilly's obesity franchise growth
Reaction tracking
A completed 24-hour reaction record is not available for this story yet. Newsig only publishes measured price movement when the required market data is present.
Curated by Newsig — News in. Signal out.
How the reaction data is measured · Editorial policy